Integrated Symposia

At the ESCMID/ASM conference the following Integrated Symposia will take place:


Challenges and opportunities in the development of non-traditional products in AMR


Tuesday, 4 October 2022, 12:00 - 13:00, Ograniser: CARB-X


Chair: Maria Uria-Nickelsen, PhD, Alliance Director, CARB-X


ESCMID-appointed Chair: Shampa Das, PhD, Deputy Head of Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool




  • Richard Alm, PhD, Chief Scientist, CARB-X
  • Victor Nizet , MD, Chief of the Division of Host-Microbe Systems and Therapeutics, University of California, San Diego (UCSD)
  • Tomas Doyle, PhD, GlaxoSmithKline
  • David Cook, PhD, Senior Vice President and Chief Scientific Officer, Forma Therapeutics
  • Miriam Furst-Wilmes, PhD, Clinical Assessor for Antiinfectives, DZIF Office for Scientific and Regulatory Advice



Where resistance spreads: AMR at the community level


Wednesday, 5 October 2022, 12:00 - 13:00, Organiser: GSK, Lunch boxes provided


Debating innovative solutions with multiple stakeholders.


ESCMID-appointed Chair: Alexander Lepak, University of Wisconsin, Madison, United States




  • Mark Wilcox, PhD, University of Leeds, United Kingdom
  • Rafael Canton, PhD, Complutense University, Madrid, Spain
  • Neil Pearson, GSK R&D, Collegeville, United States
  • Melissa Kramer, uUTI Free Patient Advocate, Ireland


It is an accepted premise, that without innovation and strategies in place, the treatment of drug-resistant infections will become increasingly challenging. Within the community environment, there is the potential for a ‘perfect storm’ to be created, due to the high volume of antibiotics prescribed in this setting.


WHO define Antimicrobial Resistance (AMR) as a global health and development threat, which requires urgent multisectoral action in order to achieve Sustainable Development Goals.


In this symposium the panel of experts will explore, from different angles, the need for innovative strategies and solutions in the face of AMR, and how collaboratively, industry, public health, healthcare professionals and patients can address this problem to improve outcomes for patients and society.